If regulators worldwide are to make good decisions in the face of complex risk–benefit profiles, a transparent and systematic approach is needed. I believe our ‘universal framework’ could be the answer.
1
min read
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.